Bayer announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for myBETAapp and the BETACONNECT Navigator.
With this software in relapsing-remitting multiple sclerosis, people using the electronic BETACONNECT autoinjector to administer BETASERON (interferon beta-1b) can use Bluetooth technology to connect their current autoinjector to the new myBETAapp on their mobile device or computer. Patients have the opportunity to share their injection data with their BETA Nurse and healthcare team. Viewing this data through the BETACONNECT Navigator may be a useful tool for the health care team to gain insights into patients' injection history and provide support to those taking BETASERON.
"Since introducing the first FDA approved treatment option for relapsing remitting multiple sclerosis patients more than two decades ago, we've listened closely to the community to understand their needs and how we can support them," Mark Rametta, D.O., FACOI, FACP, Bayer's medical director for Neurology said. "The myBETAapp and BETACONNECT Navigator add to the services that we've developed based on patient feedback, including 24/7 access to nurse support and the first and only electronic autoinjector for patients taking BETASERON."
The myBETAapp will be available for free download at the Apple app store, Google Play or Betaseron.com in mid-July. Patients enrolled in BETAPLUS, Bayer's comprehensive patient support program, can speak directly to a BETA Nurse, who is specially trained in MS.
The BETACONNECT autoinjector, myBETAapp and the BETACONNECT Navigator were designed and developed by Medicom Innovation Partner, headquartered in Struer, Denmark.
Multiple sclerosis is a chronically inflammatory, incurable and usually intermittent disease of the central nervous system. The most common form of multiple sclerosis is relapsing-remitting MS (RRMS), where symptoms flare up and then improve, making it critical for doctors to track the severity of the disease on a regular basis. Out of the 400,000 people living with MS in the United States, approximately 320,000 people are initially diagnosed with RRMS. Injectable beta-interferons are a prescribed class of immunomodulatory drugs for RRMS.